These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18685889)

  • 1. PET scan valuable in subset of patients with negative I-131 scan, rising thyroglobulin levels in differentiated thyroid cancer patients.
    Ramakant P; Verma AK
    World J Surg; 2008 Dec; 32(12):2742, author reply 2743. PubMed ID: 18685889
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rosiglitazone in two patients with thyroglobulin-positive and radioiodine-negative differentiated thyroid cancer: preliminary results].
    Martín T; Torres A; Cambil T; Castro J
    Med Clin (Barc); 2008 Oct; 131(11):435. PubMed ID: 18928727
    [No Abstract]   [Full Text] [Related]  

  • 3. F-18 FDG PET/CT imaging in the diagnostic work-up of thyroid cancer patients with high serum thyroglobulin, negative I-131 whole body scan and suppressed thyrotropin: 8-year experience.
    Elboga U; Karaoglan H; Sahin E; Kalender E; Demir HD; Basıbuyuk M; Zeki Celen Y; Yilmaz M; Ozkaya M
    Eur Rev Med Pharmacol Sci; 2015; 19(3):396-401. PubMed ID: 25720709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
    Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
    Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
    Altenvoerde G; Lerch H; Kuwert T; Matheja P; Schäfers M; Schober O
    Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA; Llamas-Elvira JM; Ramírez-Navarro A; Gómez MJ; Rodríguez-Fernández A; Muros T; López de la Torre M; Becerra A; Carreras JL
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P; Kohlfürst S
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas.
    Giovanella L; Ceriani L; De Palma D; Suriano S; Castellani M; Verburg FA
    Head Neck; 2012 May; 34(5):626-31. PubMed ID: 21850699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV; Borrego Dorado I; Gómez Camarero P; Rodríguez Rodríguez JR; Vázquez Albertino RJ; Navarro González E; Astorga Jiménez R
    Rev Esp Med Nucl; 2005; 24(1):5-13. PubMed ID: 15701340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 131I total body scan and serum thyroglobulin assay in the follow-up of surgically treated patients affected by differentiated thyroid carcinoma.
    Panza N; Lombardi G; Minozzi M; Salvatore M; Claudio F; Mariano A; Macchia V
    J Nucl Med Allied Sci; 1984; 28(1):9-12. PubMed ID: 6481470
    [No Abstract]   [Full Text] [Related]  

  • 13. The clinical impact of 18F-FDG PET in papillary thyroid carcinoma with a negative 131I whole body scan: a single-center study of 108 patients.
    Choi MY; Chung JK; Lee HY; So Y; Park DJ; Jeong JM; Lee DS; Lee MC; Cho BY
    Ann Nucl Med; 2006 Oct; 20(8):547-52. PubMed ID: 17134022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma.
    Frank RW; Middleton L; Stack BC; Spencer HJ; Riggs AT; Bodenner DL
    Head Neck; 2014 Feb; 36(2):155-7. PubMed ID: 23728951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroglobulin measurement vs iodine 131 total-body scan for follow-up of well-differentiated thyroid cancer.
    Aiello DP; Manni A
    Arch Intern Med; 1990 Feb; 150(2):437-9. PubMed ID: 2105703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical implication of F-18 FDG PET/CT for differentiated thyroid cancer in patients with negative diagnostic iodine-123 scan and elevated thyroglobulin.
    Kim SJ; Lee TH; Kim IJ; Kim YK
    Eur J Radiol; 2009 Apr; 70(1):17-24. PubMed ID: 18207685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
    Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
    J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The thyroglobulin level in blood: a reliable indicator of metastasis in the follow-up study of patients with functioning thyroid carcinoma].
    Sluiter WJ; Sijperda A; Piers DA; Reitsma WD; Fleuren GJ; Oosterhuis JW; Vermey A; Doorenbos H
    Ned Tijdschr Geneeskd; 1983 Jun; 127(26):1133-8. PubMed ID: 6888573
    [No Abstract]   [Full Text] [Related]  

  • 19. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM; Cuenca-Cuenca JI; Ruiz-Franco-Baux J; Borrego-Dorado I; Tirado-Hospital JL; Navarro-González E; Vázquez-Albertino R
    Rev Esp Med Nucl Imagen Mol; 2012; 31(6):315-21. PubMed ID: 23084014
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What is the role of florine-18 fluorodeoxyglucose/positron emission tomography/computed tomography imaging in well-differentiated thyroid cancers with negative iodine-131 scan high thyroglobulin and normal anti-thyroglobulin levels.
    Döner RK; Sager S; Görtan FA; Topuz ÖV; Akyel R; Vatankulu B; Baran A; Teksoz S; Sönmezoglu K
    J Cancer Res Ther; 2016; 12(2):1010-7. PubMed ID: 27461690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.